Clinical and Genetic Characterization of Individuals With Achromatopsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01846052
Recruitment Status : Completed
First Posted : May 3, 2013
Last Update Posted : October 13, 2017
National Eye Institute (NEI)
Information provided by (Responsible Party):
Applied Genetic Technologies Corp

Brief Summary:
The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.

Condition or disease

Detailed Description:
Individuals with a clinical diagnosis of achromatopsia will be asked to provide informed consent and will then have a single 5 mL blood sample drawn for DNA sequence analysis of genes known to cause achromatopsia, including the CNGB3 gene. All participants will be informed of the results of testing for these mutations. Those with mutations in both alleles of the CNGB3 gene will be evaluated every 6 months for up to 1.5 years by using a variety of non-invasive visual function tests to more fully characterize their clinical condition. This testing will include routine ophthalmic examination and tests of visual acuity, color vision, reading speed, perimetry, nystagmus, light sensitivity, optical coherence tomography, adaptive optics retinal imaging, electroretinography, fundus photography and completion of a quality of life questionnaire.

Study Type : Observational
Actual Enrollment : 56 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical and Genetic Characterization of Individuals With Achromatopsia
Study Start Date : June 2013
Primary Completion Date : April 2017
Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Visual acuity [ Time Frame: Annually for up to 1.5 years ]
    Visual acuity will be measured by EVA or ETDRS methods

Secondary Outcome Measures :
  1. Color Vision [ Time Frame: annually for up to 1.5 years ]
    Color vision will be measured by Farnsworth D-15 test and anomaloscope

  2. Adaptive Optics Retinal Imaging [ Time Frame: annually for up to 1.5 years ]
    Adaptive optics retinal imaging will be performed using the method of Genead et al. (Invest Ophthalmol Vis Sci 2011;52:7298-308).

Biospecimen Retention:   Samples With DNA
DNA samples will be stored at the DNA testing laboratory for additional testing for mutations in other genes that may be causally related to achromatopsia.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with a clinical diagnosis of achromatopsia

Inclusion Criteria:

  1. Clinical diagnosis of achromatopsia (screening portion of study);
  2. Molecular confirmation of mutations in the CNGB3 gene (main portion of study);
  3. At least 6 years of age;
  4. Willing and able to perform study procedures;
  5. Signed informed consent(s) obtained (and child assent where applicable).

Exclusion Criteria:

  1. Not able to have a blood sample drawn;
  2. Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment);
  3. Participating in an interventional research study of drugs or devices for treatment of achromatopsia or other retinal diseases;
  4. Use of medications that may impair color vision (e.g. hydroxychloroquine);
  5. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01846052

United States, Florida
VitreoRetinal Associates
Gainesville, Florida, United States, 32607
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
United States, Illinois
Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp
Chicago, Illinois, United States, 60608
United States, Oregon
Casey Eye Institute, Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Applied Genetic Technologies Corp
National Eye Institute (NEI)
Study Director: Matt Feinsod, MD Applied Genetics Technologies Corporation

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Applied Genetic Technologies Corp Identifier: NCT01846052     History of Changes
Other Study ID Numbers: ACHM-001
1R24EY022023 ( U.S. NIH Grant/Contract )
First Posted: May 3, 2013    Key Record Dates
Last Update Posted: October 13, 2017
Last Verified: October 2017

Keywords provided by Applied Genetic Technologies Corp:
achromatopsia, CNGB3

Additional relevant MeSH terms:
Color Vision Defects
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms